A study published last month suggested the drugs could result in reduced hip and spine bone mineral density when used without exercise, adding to concerns patients could lose muscle mass while taking GLP-1 drugs for weight loss
The future of semaglutide and similar GLP-1 agonists looks bright as we continue to understand their complex effects on multiple body systems
IGF-1 pathway peptides (IGF-1, IGF-1 LR3): Hypoglycemia is the most acute risk
Clinical perspective SGLT2is and GLP-1RAs exhibit clinical benefits on glycemic control, systolic blood pressure (SBP), body weight, and dyslipidemia, which may all partly contribute to the cardiovascular protection provided by these two drug classes [4, 19]
While these drugs can be life-changing, they also come with significant costs for the employers who choose to cover them
22 Reduced porin expression significantly limits their uptake, which leads to resistance against these drugs